Meryem Aktan1, Hilal Kiziltunc Ozmen2. 1. Department of Radiation Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey. 2. Department of Radiation Oncology, Atatürk University School of Medicine, Erzurum, Turkey.
Abstract
OBJECTIVE: Treatment planning is primarily based on the tumor node metastasis (TNM) staging system for head and neck cancer (HNC). However, TNM does not give sufficient information about biological aggressiveness, treatment response, and prognosis. New molecular markers are needed for individualized cancer treatment. Apelin is a bioactive peptide and an endogenous ligand for the G protein-coupled receptor (APJ). Its expression is induced under hypoxic conditions. Apelin and its receptor APJ are important factors in physiological angiogenesis and may be novel targets for anti-angiogenic tumor therapies. This preliminary study aimed to investigate whether there was a difference in serum apelin levels between patients with HNC and control group and also to compare the serum apelin levels before and after radiotherapy. MATERIALS AND METHODS: Twenty-two patients with HNC (patient group) and 30 healthy individuals (control group) were included in the study. In the patient group, blood samples were collected before and after radiotherapy. Serum apelin-36 levels were measured by enzyme-linked immunosorbent assay. RESULTS: Serum apelin-36 levels were significantly higher in patients with HNC than in the control group (p<0.001). Coverage of the measured apelin-36 levels showed a significant decrease after radiotherapy according to the levels before radiotherapy. There was no statistically significant difference between the groups (p>0.05). CONCLUSION: Apelin may be a potential therapeutic target and a novel biomarker. Additional studies are needed to reveal the relationships between serum apelin and radiotherapy in solid human tumors.
OBJECTIVE: Treatment planning is primarily based on the tumor node metastasis (TNM) staging system for head and neck cancer (HNC). However, TNM does not give sufficient information about biological aggressiveness, treatment response, and prognosis. New molecular markers are needed for individualized cancer treatment. Apelin is a bioactive peptide and an endogenous ligand for the G protein-coupled receptor (APJ). Its expression is induced under hypoxic conditions. Apelin and its receptor APJ are important factors in physiological angiogenesis and may be novel targets for anti-angiogenic tumor therapies. This preliminary study aimed to investigate whether there was a difference in serum apelin levels between patients with HNC and control group and also to compare the serum apelin levels before and after radiotherapy. MATERIALS AND METHODS: Twenty-two patients with HNC (patient group) and 30 healthy individuals (control group) were included in the study. In the patient group, blood samples were collected before and after radiotherapy. Serum apelin-36 levels were measured by enzyme-linked immunosorbent assay. RESULTS: Serum apelin-36 levels were significantly higher in patients with HNC than in the control group (p<0.001). Coverage of the measured apelin-36 levels showed a significant decrease after radiotherapy according to the levels before radiotherapy. There was no statistically significant difference between the groups (p>0.05). CONCLUSION: Apelin may be a potential therapeutic target and a novel biomarker. Additional studies are needed to reveal the relationships between serum apelin and radiotherapy in solid human tumors.
Entities:
Keywords:
Apelin; head and neck cancer; radiotherapy
Authors: Y Kawamata; Y Habata; S Fukusumi; M Hosoya; R Fujii; S Hinuma; N Nishizawa; C Kitada; H Onda; O Nishimura; M Fujino Journal: Biochim Biophys Acta Date: 2001-04-23
Authors: Christopher M Cox; Susan L D'Agostino; Melanie K Miller; Ronald L Heimark; Paul A Krieg Journal: Dev Biol Date: 2006-04-27 Impact factor: 3.582
Authors: Alexander J Glassford; Patrick Yue; Ahmad Y Sheikh; Hyung J Chun; Shirin Zarafshar; Denise A Chan; Gerald M Reaven; Thomas Quertermous; Philip S Tsao Journal: Am J Physiol Endocrinol Metab Date: 2007-09-18 Impact factor: 4.310
Authors: Song Han; Guiyun Wang; Xiang Qi; Heung M Lee; Ella W Englander; George H Greeley Journal: Am J Physiol Regul Integr Comp Physiol Date: 2008-03-26 Impact factor: 3.619
Authors: Roland E Kälin; Martin P Kretz; Andrea M Meyer; Andreas Kispert; Frank L Heppner; André W Brändli Journal: Dev Biol Date: 2007-03-12 Impact factor: 3.582